1160 related articles for article (PubMed ID: 27820943)
21. Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease.
Lattanzi A; Camarena J; Lahiri P; Segal H; Srifa W; Vakulskas CA; Frock RL; Kenrick J; Lee C; Talbott N; Skowronski J; Cromer MK; Charlesworth CT; Bak RO; Mantri S; Bao G; DiGiusto D; Tisdale J; Wright JF; Bhatia N; Roncarolo MG; Dever DP; Porteus MH
Sci Transl Med; 2021 Jun; 13(598):. PubMed ID: 34135108
[TBL] [Abstract][Full Text] [Related]
22. Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice.
Everette KA; Newby GA; Levine RM; Mayberry K; Jang Y; Mayuranathan T; Nimmagadda N; Dempsey E; Li Y; Bhoopalan SV; Liu X; Davis JR; Nelson AT; Chen PJ; Sousa AA; Cheng Y; Tisdale JF; Weiss MJ; Yen JS; Liu DR
Nat Biomed Eng; 2023 May; 7(5):616-628. PubMed ID: 37069266
[TBL] [Abstract][Full Text] [Related]
23. CRISPR/Cas9 system and its applications in human hematopoietic cells.
Hu X
Blood Cells Mol Dis; 2016 Nov; 62():6-12. PubMed ID: 27736664
[TBL] [Abstract][Full Text] [Related]
24. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.
Traxler EA; Yao Y; Wang YD; Woodard KJ; Kurita R; Nakamura Y; Hughes JR; Hardison RC; Blobel GA; Li C; Weiss MJ
Nat Med; 2016 Sep; 22(9):987-90. PubMed ID: 27525524
[TBL] [Abstract][Full Text] [Related]
25. Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells.
Moiani A; Letort G; Lizot S; Chalumeau A; Foray C; Felix T; Le Clerre D; Temburni-Blake S; Hong P; Leduc S; Pinard N; Marechal A; Seclen E; Boyne A; Mayer L; Hong R; Pulicani S; Galetto R; Gouble A; Cavazzana M; Juillerat A; Miccio A; Duclert A; Duchateau P; Valton J
Nat Commun; 2024 Jun; 15(1):4965. PubMed ID: 38862518
[TBL] [Abstract][Full Text] [Related]
26. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.
Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644
[TBL] [Abstract][Full Text] [Related]
27. Generation of an in vitro model of β-thalassemia using the CRISPR/Cas9 genome editing system.
Ajami M; Atashi A; Kaviani S; Kiani J; Soleimani M
J Cell Biochem; 2020 Feb; 121(2):1420-1430. PubMed ID: 31596028
[TBL] [Abstract][Full Text] [Related]
28. Development of gene editing strategies for human β-globin (HBB) gene mutations.
Kalkan BM; Kala EY; Yuce M; Karadag Alpaslan M; Kocabas F
Gene; 2020 Apr; 734():144398. PubMed ID: 31987908
[TBL] [Abstract][Full Text] [Related]
29. Correction of Hemoglobin E/Beta-Thalassemia Patient-Derived iPSCs Using CRISPR/Cas9.
Wattanapanitch M
Methods Mol Biol; 2021; 2211():193-211. PubMed ID: 33336279
[TBL] [Abstract][Full Text] [Related]
30. Efficient gene correction of an aberrant splice site in β-thalassaemia iPSCs by CRISPR/Cas9 and single-strand oligodeoxynucleotides.
Xiong Z; Xie Y; Yang Y; Xue Y; Wang D; Lin S; Chen D; Lu D; He L; Song B; Yang Y; Sun X
J Cell Mol Med; 2019 Dec; 23(12):8046-8057. PubMed ID: 31631510
[TBL] [Abstract][Full Text] [Related]
31. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Frangoul H; Altshuler D; Cappellini MD; Chen YS; Domm J; Eustace BK; Foell J; de la Fuente J; Grupp S; Handgretinger R; Ho TW; Kattamis A; Kernytsky A; Lekstrom-Himes J; Li AM; Locatelli F; Mapara MY; de Montalembert M; Rondelli D; Sharma A; Sheth S; Soni S; Steinberg MH; Wall D; Yen A; Corbacioglu S
N Engl J Med; 2021 Jan; 384(3):252-260. PubMed ID: 33283989
[TBL] [Abstract][Full Text] [Related]
32. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
Wen J; Tao W; Hao S; Zu Y
J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
[TBL] [Abstract][Full Text] [Related]
33. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells.
Hoban MD; Cost GJ; Mendel MC; Romero Z; Kaufman ML; Joglekar AV; Ho M; Lumaquin D; Gray D; Lill GR; Cooper AR; Urbinati F; Senadheera S; Zhu A; Liu PQ; Paschon DE; Zhang L; Rebar EJ; Wilber A; Wang X; Gregory PD; Holmes MC; Reik A; Hollis RP; Kohn DB
Blood; 2015 Apr; 125(17):2597-604. PubMed ID: 25733580
[TBL] [Abstract][Full Text] [Related]
34. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus.
Antoniani C; Meneghini V; Lattanzi A; Felix T; Romano O; Magrin E; Weber L; Pavani G; El Hoss S; Kurita R; Nakamura Y; Cradick TJ; Lundberg AS; Porteus M; Amendola M; El Nemer W; Cavazzana M; Mavilio F; Miccio A
Blood; 2018 Apr; 131(17):1960-1973. PubMed ID: 29519807
[TBL] [Abstract][Full Text] [Related]
35. Induction of therapeutic levels of HbF in genome-edited primary β
Mingoia M; Caria CA; Ye L; Asunis I; Marongiu MF; Manunza L; Sollaino MC; Wang J; Cabriolu A; Kurita R; Nakamura Y; Cucca F; Kan YW; Marini MG; Moi P
Br J Haematol; 2021 Jan; 192(2):395-404. PubMed ID: 33216968
[TBL] [Abstract][Full Text] [Related]
36. Nuclease-stimulated homologous recombination at the human β-globin gene.
Vannocci T; Kurata H; de la Fuente J; Roberts IA; Porter AC
J Gene Med; 2014; 16(1-2):1-10. PubMed ID: 24590875
[TBL] [Abstract][Full Text] [Related]
37. Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin.
Ravi NS; Wienert B; Wyman SK; Bell HW; George A; Mahalingam G; Vu JT; Prasad K; Bandlamudi BP; Devaraju N; Rajendiran V; Syedbasha N; Pai AA; Nakamura Y; Kurita R; Narayanasamy M; Balasubramanian P; Thangavel S; Marepally S; Velayudhan SR; Srivastava A; DeWitt MA; Crossley M; Corn JE; Mohankumar KM
Elife; 2022 Feb; 11():. PubMed ID: 35147495
[TBL] [Abstract][Full Text] [Related]
38. Highly efficient therapeutic gene editing of human hematopoietic stem cells.
Wu Y; Zeng J; Roscoe BP; Liu P; Yao Q; Lazzarotto CR; Clement K; Cole MA; Luk K; Baricordi C; Shen AH; Ren C; Esrick EB; Manis JP; Dorfman DM; Williams DA; Biffi A; Brugnara C; Biasco L; Brendel C; Pinello L; Tsai SQ; Wolfe SA; Bauer DE
Nat Med; 2019 May; 25(5):776-783. PubMed ID: 30911135
[TBL] [Abstract][Full Text] [Related]
39. Adeno-associated virus 2-mediated transduction and erythroid lineage-restricted expression from parvovirus B19p6 promoter in primary human hematopoietic progenitor cells.
Kurpad C; Mukherjee P; Wang XS; Ponnazhagan S; Li L; Yoder MC; Srivastava A
J Hematother Stem Cell Res; 1999 Dec; 8(6):585-92. PubMed ID: 10645765
[TBL] [Abstract][Full Text] [Related]
40. In vivo base editing by a single i.v. vector injection for treatment of hemoglobinopathies.
Li C; Georgakopoulou A; Newby GA; Everette KA; Nizamis E; Paschoudi K; Vlachaki E; Gil S; Anderson AK; Koob T; Huang L; Wang H; Kiem HP; Liu DR; Yannaki E; Lieber A
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36006707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
